A review of PARP inhibitors: from bench to bedside (Q37774151)

23 August 2017

1 reference

title

A review of PARP inhibitors: from bench to bedside (English)

1 reference

23 August 2017

C Underhill

1

1 reference

23 August 2017

M Toulmonde

series ordinal

2

1 reference

23 August 2017

H Bonnefoi

series ordinal

3

1 reference

23 August 2017

publication date

19 July 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

268-279

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Instability and decay of the primary structure of DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Targeted therapy for cancer using PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Involvement of Brca2 in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Mutator pathways unleashed by epigenetic silencing in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Gene-Expression Profiles in Hereditary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Reduction of BRCA1 expression in sporadic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

PARP inhibitor development for systemic cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ322

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ322

1 reference

release_jgmra2azz5fbfksou3jzk7vx2i

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jgmra2azz5fbfksou3jzk7vx2i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference